Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

PsychoGenics and Sunovion Pharmaceuticals Inc. Expand Partnership

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
Companies announced that they have expanded the scope of their CNS drug discovery partnership and extended the agreement for another two years.

The expanded agreement builds on the success of the partnership that has given rise to several CNS discovery programs. Sunovion and PsychoGenics will continue to advance existing discovery programs as well as screen new diverse compound libraries in vivo using PsychoGenics’ proprietary SmartCube® System and broad preclinical capabilities, with the aim of identifying new therapies for CNS disorders.

“The phenotypic approach to drug discovery has historically yielded many of the most important CNS drugs,” said Tom Large, Senior Vice President of Discovery Research at Sunovion Pharmaceuticals Inc. “The PsychoGenics and Sunovion team has rapidly and efficiently utilized the rich behavioral data of SmartCube to drive chemistry optimization efforts. This has yielded a drug-like molecule with novel pharmacology.”

“We are delighted to expand our shared-risk partnership with Sunovion which has already delivered a clinical candidate. We have enjoyed an excellent working relationship with the talented Sunovion discovery team and look forward to advancing existing discovery programs and pursuing new research programs together,” remarked Emer Leahy, Ph.D., PsychoGenics’ President & Chief Executive Officer.

PsychoGenics’ technologies, which include its SmartCube® system, combine broad in vivo behavioral expertise with developments in robotics, computer vision, and bioinformatics to phenotypically evaluate drug candidates for potential utility across the spectrum of CNS disease indications. Working in partnership with pharmaceutical and biotech companies, PsychoGenics has been instrumental in identifying therapeutic potential for discontinued compounds; as well as, early stage compounds with novel mechanisms of action.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos